target upgrad unit state go sg bsite
mix sale fy ep guidanc upgrad help lower tax
upsid tp
chang sinc last report
nc chang
sale broadli line diabet portfolio lacklustr
nevertheless ep guidanc lift consensu
help lower tax rate hold rate reiter tp
surpris group sale rose constant exchang rate cer
broadli line consensu group endocrinolog drug miss
sole except trulic diabet weekli compet directli
novo ozemp victoza
grow significantli
line
consensu fast-grow market us benefit
launch novo next-gener ozemp increas evid
benefit class patient see oct report hot topic diabet
easd note earlier week lilli report posit headlin result trulic
larg outcom trial call rewind basaglar lilli biosimilar version sanofi
lantu light consensu confirm materi price pressur us
sale recent launch taltz direct competitor novarti cosentyx psoriasi
match consensu better perform tail portfolio off-set
slightli weaker cancer neurosci sale elanco anim health group
sale return growth beat consensu list elanco
lilli stake plan divest entir hold within one year adj
ep consensu help notabl lower tax rate
spend despit higher sg cost
guidanc back lower tax rate vs group
narrow sale guidanc non-
ep
hold rate reiter tp rais edg estim reflect
number higher guidance/low tax rate rais target price accordingli also
take account higher pharma comparison multipl mark market elanco
reiter hold rate given alreadi high consensu expect pipelin
despit earn grow line sector due patent expiri ahead
stock trade price-to-earnings premium pharma sector larg
speed fundament catalyst day decemb ny
smith
societ general sg seek busi compani cover research report result investo rs ho uld awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
eli lilli simplifi select ed product
trulicit weekli us prescript ion market
humalog short -act ing insulin us prescript ion market
sg valuat ion tp increas
anim market price
margin
regulatori approv japan alreadi approv us eu
outcom trial rewind headlin announc detail data come
next diabet congress ada june like
hare asic year end/outstand
share rice average hist yr current
valu minor
valu financi invest
ep reciat amortis
chang work capit
ca flow oper activ
ca flow invest activ
ca flow financ activ
net chang cash result cf
intang
report complet nov cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part co mpensat
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari ondon new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
tp deriv sotp dcf order captur short term perform lt opportun pipelin sotp
averag valuat given use larg pharma ev/ebita multipl premium pharma divis market va lue
anim health dcf lt growth lt ebita margin wacc
downsid stronger competit recent launch product cancer immun -inflamm low mid singl digit
upsid better penetr talz psoriasi high-single-digit upsid ebit
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
equit rat ing dispers relat ionship
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
se ctor weight definit month period
sector weight assign sg equiti rese arch
strategist distinct separ sg equiti research
analyst rate base relev
overw eight sector expect outperform relevan br
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underw eight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc ith
prior written permiss inform int llectual properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assu me en tir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind mor
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act joint bookrunn bond issu
sg act joint bookrunn hochtief ag bond issu eur
sg act advisor acs/hochtief acquisit aberti
sg act co-manag novarti financ sa bond issu senior
sg act global co-ordin sanofi multi-tranch senior bond issu eur yr yr yr yr yr yr
